NEW YORK, Jan. 25, 2024 /PRNewswire/ — The Global Tyrosine Kinase Inhibitors Market is set for substantial growth, projecting a Compound Annual Growth Rate (CAGR) of 8.42%, as reported by Technavio. The market is expected to experience a rise of USD 24.22 billion between 2023 and 2028, fueled by the increasing prevalence of patient assistance programs (PAPs) and their significant impact on the uptake of Tyrosine Kinase Inhibitors (TKIs).Gain insights into market scenarios with historical data spanning from 2018 to 2022 and future projections for the period 2024-2028. View free sample report.
Technavio has announced its latest market research report titled Global Tyrosine Kinase Inhibitors Market 2024-2028
Key Drivers, Trends, and Challenges:
Analyzing data from 2023 as the base year, the report highlights key drivers influencing market growth, notably the pivotal role of PAPs in enhancing patient access to expensive or specialized medications like TKIs. The adoption of TKIs is recognized as a crucial trend, driven by the financial assistance, co-pay support, and medication provision facilitated by PAPs. However, challenges arise from the high cost of currently available TKIs, potentially limiting patient adherence to treatment. Some companies in the market, including Novartis AG, AbbVie Inc., and AstraZeneca Plc, are strategically positioning themselves to strengthen their market presence. The report offers detailed analyses of 20 market companies, categorizing them based on key factors and market dominance. Obtain comprehensive company information with a purchase today.
Market Segmentation Overview:
The market is aligned for a significant growth, particularly in the offline distribution channel segment, valued at USD 24.71 billion in 2018. North America is forecasted to contribute 39% to the global market growth during the forecast period. The report further segments the market based on distribution channels, products (RTKIs and nRTKIs), and geography. The Tyrosine Kinase Inhibitors market is on the verge of noteworthy expansion, driven by factors reshaping the healthcare landscape. Explore growth analysis by revenue at global, regional, and country levels, discover market trends, growth opportunities, and conduct a thorough analysis for the forecasted period. Obtain actionable insights to stay ahead in an ever-evolving market landscape. Download Free Sample Report.
Related Reports:
The idiopathic pulmonary fibrosis market size is estimated to increase by USD 1.3 billion at a CAGR of 6.68% between 2022 and 2027 .
The global gene panel market size is estimated to grow by USD 3.24 billion at a CAGR of 18.21% between 2022 and 2027.
Table of Content:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
About US
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
